Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
11/11/2019
1
Cardiovascular Disease 2019 Update: Important Bits & Pieces from Recent Studies
William L. Baker, Pharm.D., FCCP, FACC, FAHA
Associate Professor
University of Connecticut School of Pharmacy
Department of Pharmacy Practice
@wbaker0621
• I have no disclosures germane to the content of this presentation.
Disclosures
• Discuss the role of SGLT-2 inhibitors in the management of heart failure
• Describe the pharmacologic options for management of heart failure with preserved ejection fraction
• Identify the role of PUFAs for managing hyperlipidemia and cardiovascular disease
• Describe the modern role of aspirin for primary and secondary cardiovascular prevention
Learning Objectives
Advances in Heart Failure with Reduced Ejection Fraction
2019 ADA Guidelines: Pharmacologic Approach to Glycemic Treatment
Metformin + Lifestyle Management
Established ASCVD
ASCVD Predominates Heart Failure
GLP-1 RA OR
SGLT2i
SGLT2i (preferred)GLP-1 RA (if SGLT2i not
tolerated)
If HbA1c above target If HbA1c above target
Add other classDPP-4i
Basal insulinTZD or SU
Avoid TZDChoose agent with CV safety (DPP-4i, basal insulin, SU)
Modified From: American Diabetes Association. Diabetes Care. 2019;42(Suppl. 1):S90-S102.
SGLT-2i & HF Hospitalization
Zelker TA, et al. Lancet. 2019;393:31-9.
11/11/2019
2
No Association Between HbA1c Reduction & Heart Failure Hospitalization
Kramer CK, et al. J Am Coll Cardiol HF. 2018;6:823-30.
SGLT2 Inhibition & Effects on Myocardial Na+/H+ Exchange
Verma S, et al. Diabetologia. 2018;61:2108-17.
• 97 pts with T2DM & established CAD (LVEF >30%)
• Randomized to empagliflozin 10 mg/d or placebo X 6 months
• 1 outcome: Change in LV mass (baseline ~60 g/m2)
• 2 outcomes: LVEDV, LVESV, LVEF
• Biomarkers (NT-proBNP, sST2, troponin I)
RCT of Empagliflozin on LV Structure/Function in T2DM & CHD: EMPA-HEART CardioLink-6 Trial
-2.6
-1
2.2
-0.1
0.04
-0.1
-3
-2
-1
0
1
2
3LV Mass
index (g/m2)p=0.01
LVESV (ml/m2)p=0.36
LVEF (%) p=0.07
Empagliflozin
Placebo
Natila A, et al. Cardiovasc Diabetol. 2017;16:130.Verma S. AHA 2018 Scientific Sessions, Nov 10-12, 2018. LBS.05 McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
• Key inclusion criteria: Symptomatic HF; EF ≤ 40%; NT-proBNP ≥ 600 pg/mL (if hospitalized for HF within last 12 months ≥ 400 pg/mL; if atrial fibrillation/flutter ≥ 900 pg/mL)
• Key exclusion criteria: eGFR <30 mL/min; symptomatic hypotension or SBP <95 mmHg; type 1 diabetes mellitus
• Primary endpoint: Worsening HF event or cardiovascular death (worsening HF event = unplanned HF hospitalization or an urgent HF visit requiring IV therapy)
DAPA-HF: Trial Design
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
Characteristic Dapagliflozin (n=2373) Placebo (n=2371)
Mean age (yr) 66 67
Male (%) 76 77
NYHA class II/III/IV (%) 68/31/1 67/32/1
Mean LVEF (%) 31 31
Median NT-proNP (pg/mL) 1428 1466
Mean systolic BP (mmHg) 122 122
Ischemic etiology (%) 55 57
Mean eGFR (mL/min) 66 66
Prior diagnosis T2DM (%) 42 42
Any baseline T2DM (%) 45 45
DAPA-HF: Key Baseline Characteristics
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
11/11/2019
3
Treatment (%) Dapagliflozin (n=2373) Placebo (n=2371)
Diuretic 93 94
RAAS Inhibitor 94 93
ACE Inhibitor 56 56
ARB 28 27
Sacubitril/valsartan 11 11
Beta-blocker 96 96
MRA 71 71
ICD 26 26
CRT 8 7
DAPA-HF: Baseline Treatment
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
DAPA-HF: Primary Outcome (CV Death/HF Event)
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
NNT =21
DAPA-HF: CV Death & All-Cause Mortality
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
Cardiovascular Death All-Cause Mortality
DAPA-HF: No Diabetes/Diabetes Subgroup
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
DapagliflozinN=2,373
PlaceboN=2,371
HR (95%CI)
All patients 386/2373 502/2371 0.74 (0.65, 0.85)
Type 2 diabetes at baseline
Yes 215/1075 271/1064 0.75 (0.63, 0.90)
No 171/1298 231/1307 0.73 (0.60, 0.88)
0.00 0.50 1.00 1.50
Favors Dapagliflozin Favors Placebo
Adverse Event (%) Dapagliflozin (n=2368) Placebo (n=2368) P-value
Volume depletion 7.5 6.8 0.40
Renal ADEs 6.5 7.2 0.36
Volume depletion 1.2 1.7 0.23
Fracture 2.1 2.1 1.00
Amputation 0.5 0.5 1.00
Major hypoglycemia 0.2 0.2 -
Diabetic ketoacidosis 0.1 0.0 -
ADE Leading to DC 4.7 4.9 0.79
Any Serious ADE 38 42 <0.01
DAPA-HF: Safety/Adverse Events
McMurray JJV, et al. N Engl J Med. 2019 Sep 19. [Epub ahead of print]
Relative Risk 2 Year Mortality
None -- 35.0%
ARNI ↓ 28% 25.2%
Beta-blocker ↓ 35% 16.4%
Aldosterone Antagonist ↓ 30% 11.5%
SGLT2 Inhibitor ↓ 17% 9.5%
Cumulative Impact of Evidence-Based HFrEFMedical Therapies on All-Cause Mortality
Fonarow GC, et al. Am Heart J. 2011;161:1024-30.Fonarow GC, et al. Lancet. 2008;372:1195-6.
• Cumulative risk reduction in mortality if all evidence-based medical therapies are used:
• Relative risk reduction = 72.9%• Absolute risk reduction = 25.5%• NNT = 3.9
11/11/2019
4
• Which of the following would be the most appropriate candidate to begin an SGLT-2?
A. A 57-year-old woman with type 2 diabetes, ischemic cardiomyopathy (EF 30%) due to an MI, atrial fibrillation
B. A 47-year-old man with type 2 diabetes uncontrolled on metformin
C. A 65-year-old woman without diabetes and with HFrEF controlled on an ARNI, beta-blocker, aldosterone antagonist and diuretic
D. An SGLT-2 inhibitor could reasonable be initiated in each of the above people
Self-Assessment Question
Advances in Heart Failure with Preserved Ejection Fraction
Yusuf S, et al. Lancet. 2003;362:777. Cleland JGF, et al. Eur Heart J. 2006;27:2338.Massie BM, et al. NEJM. 2008;359:2456.; Ahmed A, et al. Circulation. 2006;114:397
DIG Trial Substudy
• No mortality or HF hospbenefit
I-PRESERVE• No mortality or
HF hospbenefit
CHARM-Preserved
• Slight benefit after adjustment for BL differences
PEP-HF• No mortality• Maybe lower
HF hosp• High study
crossover rate
TOPCAT: Spironolactone in HFpEF
Pitt B, et al. N Engl J Med. 2014;370:1383.Pfeffer MA, et al. Circulation. 2015;131:34.
Primary Endpoint* Regional Outcome Variation
* Composite of CV death, aborted cardiac arrest, or HF hospitalization
HFpEF & HFrEF: Similar HF Hospitalization & Mortality Rates
Wikstrom et al. ESC 2011 Gothenburg, Sweden, 21–24 May 2011. Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
11/11/2019
5
• Key inclusion criteria: Symptomatic HF (NYHA class II-IV); EF ≥ 45%; NT-proBNP ≥ 600 pg/mL (if hospitalized for HF within last 12 months ≥ 400 pg/mL; if atrial fibrillation/flutter ≥ 900 pg/mL); receiving diuretic therapy
• Key exclusion criteria: LVEF <40%, ACS/CV Surgery within 3 months, clinical event within 6 months, history of angioedema, eGFR < 30 mL/min/1.73 m2, serum potassium > 5.2 mEq/L
• Primary endpoint: Total (first and recurrent) hospitalizations for heart failure and death from CV causes
PARAGON-HF: Trial Design
Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
Characteristic (%) Sacubitril-Valsartan (n=2407) Valsartan (n=2389)
Diuretic 95.3 95.9
ACE-I or ARB 86.2 86.4
Beta-blocker 79.9 79.5
MRA 24.6 27.1
PARAGON-HF: Baseline Treatment
Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
• Age = 72.2 ± 8.4 years
• Female sex = ~ 52%
• Black race = ~ 2%
• Ischemic cause = ~36%
• Hypertension = ~ 95%
• Diabetes = ~43%
• Atrial fibrillation = ~32%
• Hosp for HF = ~48%
PARAGON-HF: Primary Outcome (CV Death/HF Event)
Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
RR 0.87 (0.75-1.01)p = 0.06
PARAGON-HF: Individual Components
HF Hospitalizations
CV Death
Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
RR 0.85 (0.72-1.00)p = 0.056
HR 0.95 (0.79-1.16)p = 0.62
PARAGON-HF: Secondary Endpoints
Solomon SD, et al. N Engl J Med. 2019;381:1609-20.
How Should We Most Optimally Manage HFpEFPatients?
11/11/2019
6
• Which of the following is the most appropriate interpretation of the topline findings from the PARAGON-HF Trial?
A. The trial was negative, throw the baby away with the bath water
B. Sacubitril-valsartan did not significantly lower the rate of CV death or HF hospitalization in HFpEF
C. Please, please for the love of everything holy stop conducting HFpEFtrials until we have a better understanding of what HFpEF is
D. All of the above
Self-Assessment Question
PUFA for Treating Hyperlipidemia and Cardiovascular Disease
Triglycerides a Causal Risk Factor?
Libby P. Eur Heart J. 2015;36:774-6.
Impact of EPA Along the Atherosclerosis Pathway
Nelson JR, et al. Postgrad Med. 2017;129:822-7.
Key Triglyceride-Lowering Trials Over the Last 2 Decades
Patel PN, et al. Curr Opin Cardiol. 2019;34:721-7.
Omega-3 Fatty Acids: Rx Products
ProductEPA (mg)
Per capsule
DHA (mg)Per
capsuleDosing
Take with food?
% △ TG % △ LDL-C
Omega-3 acid ethyl esters (Lovaza®)#
465 3754g QD
or2g BID
With our without
↓ 30-50 ↑ 0-45*
Icosapent ethyl (Vascepa®) 1000 -- 2g BID Yes ↓ 30-60 ↓ 0-5*
Omega-3carboxylic acids (Epanova®)
850 150 2-4g QD With our without
↓ 20-30 ↑ 0-26*
*When used as monotherapy#Lovaza® generic available as of 2014
11/11/2019
7
Low-Dose (<2g/d) Omega-3 Mixtures Show No Significant Cardiovascular Benefit
Aung T, et al. JAMA Cardiol. 2018;3:225-34.
JELIS: CV Risk Reduction with EPA in Japanese Hypercholesterolemic Patients
Yokoyama M, et al. Lancet. 2007;369:1090-8.
EPA and DHA Have Differing Effects on Cellular Membranes
Scherratt SCR & Mason RP. Chem Phys Lipids. 2018;212:73-9. Bhatt DL, et al. N Engl J Med. 2018;380:11-22.
REDUCE-IT: Primary Outcome (CV Death/HF Event)
Bhatt DL, et al. N Engl J Med. 2018;380:11-22.
REDUCE-IT: Primary Outcome (CV Death/HF Event)
Bhatt DL, et al. N Engl J Med. 2018;380:11-22.
HR 0.75 (95% CI 0.68-0.83)RRR = 24.8%NNT = 21 (95% CI 15-33)p = 0.00000001
11/11/2019
8
REDUCE-IT: Additional Outcomes
Bhatt DL, et al. N Engl J Med. 2018;380:11-22.
REDUCE-IT: Endpoints by Baseline TG Tertiles
Bhatt DL, et al. N Engl J Med. 2018;380:11-22.
• A 51-year-old man presents with diabetes, HTN, hypertriglyceridemia, and history of acute pancreatitis. Current medications include lisinopril, chlorthalidone, amlodipine, rosuvastatin 20 mg/d, metformin, and insulin glargine. His A1c=6.9%, TC 157 mg/dL, LDL-C 38 mg/dL, TG 1054 mg/dL? In addition to nonpharmacologic recommendations, which treatment option is best for his TG?
A. Add icosapent ethyl 2 g twice/day
B. Add niacin ER 500 mg/night
C. Add omega-3 acid ethyl esters 1 g/d
D. Increase rosuvastatin to 40 mg/d
Self-Assessment Question
In Whom Should We Be Using Aspirin for Primary Cardioprotection?
Reminder: Aspirin Mechanism of Action
Patrono C & Baigent C. Nature Rev Cardiol. 2019;16:675-86.
Antithrombotic Trialists’ (ATT) Collaboration: 2009
Antithrombotic Trialists’ Collaboration. Lancet. 2009;373:1849-60.
Serious Vascular Events6 fewer per 10,000/year
Major GI Bleeding3 more per 10,000/year
11/11/2019
9
ASCEND Study Group. N Engl J Med. 2019;379:1529-39.McNeil JJ, et al. N Engl J Med. 2018;379:1509-18.Gaziano JM, et al. Lancet. 2018;392:1036-46.
Primary Efficacy Findings of ASA Primary Prevention RCTs
ARRIVE
ASCEND Study Group. N Engl J Med. 2019;379:1529-39.McNeil JJ, et al. N Engl J Med. 2018;379:1509-18.Gaziano JM, et al. Lancet. 2018;392:1036-46.
ASPREE ASCEND
↑ major hemorrhageHR 1.38 (1.18-1.62); p<0.001
↑ GI bleeding eventsHR 2.11 (1.36-3.28); p=0.00007
↑ major bleedingHR 1.29 (1.09-1.52); p=0.003
Updated Meta-Analysis of Aspiring Use for Primary Prevention (Including Recent RCTs)
Zheng SL & Roddick AJ. JAMA. 2019;321:277-87.
NNT = 241
NNH = 210
• Aspirin ↑ risk of GI bleeding ~50% vs. no aspirin
• Patients >70 years old have sharp ↑ in GI bleed risk
• Enteric-coated aspirin does not confer protection from GI bleeding
What is the Role of Gastroprotectant Drugs?
Scally B, et al. Lancet Gastroenterol Hepatol. 2018;3:231-41.
Recommendations for Aspirin Use
COR LOE Recommendations
IIb A
1. Low‐dose aspirin (75‐100 mg orally daily) might beconsidered for the primary prevention of ASCVDamong select adults 40 to 70 years of age who are athigher ASCVD risk but not at increased bleeding risk.
III:
HarmB‐R
2. Low‐dose aspirin (75‐100 mg orally daily) should notbe administered on a routine basis for the primaryprevention of ASCVD among adults >70 years of age.
III:
HarmC‐LD
3. Low‐dose aspirin (75‐100 mg orally daily) should notbe administered for the primary prevention of ASCVDamong adults of any age who are at increased risk ofbleeding.
2019 ACC/AHA Primary Prevention Guidelines
Arnett DK, et al. Circulation. 2019;140:e563-95.
A Small Proportion of the Population Have High CVD Risk & Low Major Bleed Risk
Antithrombotic Trialists’ Collaboration. Lancet. 2009;373:1849-60. Patrono C & Baigent C. Nature Rev Cardiol. 2019;16:675-86.
11/11/2019
10
• A 51-year-old woman with type 2 diabetes approaches you at the pharmacy counter and asks whether she should take an aspirin daily. She has a family history of premature CVD but is otherwise heathy. Which would be the best advice to give her?
A. ASA may be indicated because of the her greater risk of early-onset coronary artery disease
B. ASA is not indicated for her as the bleed risk outweighs the potential benefit
C. ASA is indicated because of the patient’s apparent low bleed risk
D. ASA is not indicated because of the greater risk of ischemic stroke compared with the potential benefit
Self-Assessment Question
Thank You For Your Attention
XX